{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:07:02Z","timestamp":1793200022463,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s11912-023-01367-8","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T16:05:17Z","timestamp":1676045117000},"page":"309-323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Targeting Mesothelin in Solid Tumours: Anti-mesothelin Antibody and Drug Conjugates"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-3126","authenticated-orcid":false,"given":"Quincy","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"issue":"1","key":"1367_CR1","first-page":"181","volume":"52","author":"K Chang","year":"1992","unstructured":"Chang K, Pai LH, Batra JK, Pastan I, Willingham MC. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res. 1992;52(1):181\u20136.","journal-title":"Cancer Res"},{"issue":"3","key":"1367_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00000478-199203000-00006","volume":"16","author":"K Chang","year":"1992","unstructured":"Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol. 1992;16(3):259\u201368. https:\/\/doi.org\/10.1097\/00000478-199203000-00006.","journal-title":"Am J Surg Pathol"},{"key":"1367_CR3","doi-asserted-by":"publisher","unstructured":"Zhang YF, Phung Y, Gao W et al. New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma. Sci Rep. 2015;5:9928. https:\/\/doi.org\/10.1038\/srep09928.","DOI":"10.1038\/srep09928"},{"issue":"2","key":"1367_CR4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","volume":"12","author":"R Hassan","year":"2006","unstructured":"Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12(2):447\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1477.","journal-title":"Clin Cancer Res"},{"key":"1367_CR5","doi-asserted-by":"publisher","unstructured":"Liu X, Chan A, Tai CH, Andresson T, Pastan I. Multiple proteases are involved in mesothelin shedding by cancer cells. Commun Biol. 2020;3(1):728. https:\/\/doi.org\/10.1038\/s42003-020-01464-5.","DOI":"10.1038\/s42003-020-01464-5"},{"issue":"13","key":"1367_CR6","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","volume":"30","author":"K Hollevoet","year":"2012","unstructured":"Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30(13):1541\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.39.6671.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1367_CR7","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","volume":"27","author":"NG Ord\u00f3\u00f1ez","year":"2003","unstructured":"Ord\u00f3\u00f1ez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27(11):1418\u201328. https:\/\/doi.org\/10.1097\/00000478-200311000-00003.","journal-title":"Am J Surg Pathol"},{"key":"1367_CR8","doi-asserted-by":"publisher","unstructured":"Weidemann S, Gagelmann P, Gorbokon N, et al. Mesothelin expression in human tumors: a tissue microarray study on 12,679 tumors. Biomedicines. 2021;9(4):397.\u00a0https:\/\/doi.org\/10.3390\/biomedicines9040397. (This comprehensive study reported the mesothelin expression in normal tissues and various solid tumours and the impact of mesothelin expression in prognosis in both early- and late-stage solid tumours.)","DOI":"10.3390\/biomedicines9040397"},{"key":"1367_CR9","doi-asserted-by":"publisher","unstructured":"Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S. Challenges and controversies in the diagnosis of malignant mesothelioma: part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. J Clin Pathol. 2013;66(10):854\u201361. https:\/\/doi.org\/10.1136\/jclinpath-2013-201609.","DOI":"10.1136\/jclinpath-2013-201609"},{"key":"1367_CR10","doi-asserted-by":"publisher","unstructured":"Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S. Challenges and controversies in the diagnosis of mesothelioma: part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol. 2013;66(10):847\u201353. https:\/\/doi.org\/10.1136\/jclinpath-2012-201303.","DOI":"10.1136\/jclinpath-2012-201303"},{"key":"1367_CR11","doi-asserted-by":"publisher","unstructured":"Einama T, Yamagishi Y, Takihata Y, et al. Co-expression of mesothelin and CA125\/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients. Biomark Res. 2021;9(1):78. https:\/\/doi.org\/10.1186\/s40364-021-00335-3.","DOI":"10.1186\/s40364-021-00335-3"},{"issue":"8","key":"1367_CR12","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","volume":"20","author":"TK Bera","year":"2000","unstructured":"Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol. 2000;20(8):2902\u20136. https:\/\/doi.org\/10.1128\/MCB.20.8.2902-2906.2000.","journal-title":"Mol Cell Biol"},{"key":"1367_CR13","doi-asserted-by":"publisher","unstructured":"Shiraishi T, Sasaki T, Ikeda K, Tsukada Y, Nishizawa Y, Ito M. Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer. BMC Cancer.;19(1):1222. https:\/\/doi.org\/10.1186\/s12885-019-6424-4.","DOI":"10.1186\/s12885-019-6424-4"},{"issue":"3","key":"1367_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00428-018-02514-4","volume":"474","author":"T Shiraishi","year":"2019","unstructured":"Shiraishi T, Shinto E, Mochizuki S, et al. Mesothelin expression has prognostic value in stage \u0399\u0399\/\u0399\u0399\u0399 colorectal cancer. Virchows Arch. 2019;474(3):297\u2013307. https:\/\/doi.org\/10.1007\/s00428-018-02514-4.","journal-title":"Virchows Arch"},{"issue":"13","key":"1367_CR15","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.1245\/s10434-021-10507-y","volume":"28","author":"K Nagata","year":"2021","unstructured":"Nagata K, Shinto E, Shiraishi T, et al. Mesothelin expression is correlated with chemoresistance in stage IV colorectal cancer. Ann Surg Oncol. 2021;28(13):8579\u201386. https:\/\/doi.org\/10.1245\/s10434-021-10507-y.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"1367_CR16","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1097\/MPA.0b013e318221bed8","volume":"40","author":"T Einama","year":"2011","unstructured":"Einama T, Kamachi H, Nishihara H, et al. Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas. 2011;40(8):1276\u201382. https:\/\/doi.org\/10.1097\/MPA.0b013e318221bed8.","journal-title":"Pancreas"},{"issue":"9","key":"1367_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1080\/07357907.2021.1943747","volume":"39","author":"S Weidemann","year":"2021","unstructured":"Weidemann S, Perez D, Izbicki JR, et al. Mesothelin is commonly expressed in pancreatic adenocarcinoma but unrelated to cancer aggressiveness. Cancer Invest. 2021;39(9):711\u201320. https:\/\/doi.org\/10.1080\/07357907.2021.1943747.","journal-title":"Cancer Invest"},{"issue":"4","key":"1367_CR18","doi-asserted-by":"publisher","first-page":"422","DOI":"10.7150\/ijms.39012","volume":"17","author":"K Le","year":"2020","unstructured":"Le K, Wang J, Zhang T, et al. Overexpression of mesothelin in pancreatic ductal adenocarcinoma (PDAC). Int J Med Sci. 2020;17(4):422\u20137. https:\/\/doi.org\/10.7150\/ijms.39012.","journal-title":"Int J Med Sci"},{"key":"1367_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.biopha.2015.01.019","volume":"70","author":"IV Bayoglu","year":"2015","unstructured":"Bayoglu IV, Kucukzeybek BB, Kucukzeybek Y, et al. Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers. Biomed Pharmacother. 2015;70:190\u20135. https:\/\/doi.org\/10.1016\/j.biopha.2015.01.019.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"1367_CR20","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s10549-014-3077-5","volume":"147","author":"YR Li","year":"2014","unstructured":"Li YR, Xian RR, Ziober A, et al. Mesothelin expression is associated with poor outcomes in breast cancer. Breast Cancer Res Treat. 2014;147(3):675\u201384. https:\/\/doi.org\/10.1007\/s10549-014-3077-5.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1367_CR21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.clbc.2013.05.001","volume":"13","author":"N Parinyanitikul","year":"2013","unstructured":"Parinyanitikul N, Blumenschein GR, Wu Y, et al. Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer. 2013;13(5):378\u201384. https:\/\/doi.org\/10.1016\/j.clbc.2013.05.001.","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"1367_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/jso.22024","volume":"105","author":"K Baba","year":"2012","unstructured":"Baba K, Ishigami S, Arigami T, et al. Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol. 2012;105(2):195\u20139. https:\/\/doi.org\/10.1002\/jso.22024.","journal-title":"J Surg Oncol"},{"issue":"2","key":"1367_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4132\/jptm.2016.11.18","volume":"51","author":"SH Han","year":"2017","unstructured":"Han SH, Joo M, Kim H, Chang S. Mesothelin expression in gastric adenocarcinoma and its relation to clinical outcomes. J Pathol Transl Med. 2017;51(2):122\u20138. https:\/\/doi.org\/10.4132\/jptm.2016.11.18.","journal-title":"J Pathol Transl Med"},{"issue":"6","key":"1367_CR24","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3892\/ijo.2012.1662","volume":"41","author":"F Kawamata","year":"2012","unstructured":"Kawamata F, Kamachi H, Einama T, et al. Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. Int J Oncol. 2012;41(6):2109\u201318. https:\/\/doi.org\/10.3892\/ijo.2012.1662.","journal-title":"Int J Oncol"},{"issue":"4","key":"1367_CR25","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","volume":"20","author":"SS Kachala","year":"2014","unstructured":"Kachala SS, Bograd AJ, Villena-Vargas J, et al. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res. 2014;20(4):1020\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1862.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"1367_CR26","doi-asserted-by":"publisher","first-page":"11694","DOI":"10.18632\/oncotarget.3429","volume":"6","author":"A Thomas","year":"2015","unstructured":"Thomas A, Chen Y, Steinberg SM, et al. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget. 2015;6(13):11694\u2013703. https:\/\/doi.org\/10.18632\/oncotarget.3429.","journal-title":"Oncotarget"},{"key":"1367_CR27","doi-asserted-by":"publisher","first-page":"6860510","DOI":"10.1155\/2022\/6860510","volume":"2022","author":"H Liu","year":"2022","unstructured":"Liu H, Yan B, Chen Y, et al. Identification of potential prognostic biomarkers associated with monocyte infiltration in lung squamous cell carcinoma. Biomed Res Int. 2022;2022:6860510. https:\/\/doi.org\/10.1155\/2022\/6860510.","journal-title":"Biomed Res Int"},{"issue":"16","key":"1367_CR28","doi-asserted-by":"publisher","first-page":"26744","DOI":"10.18632\/oncotarget.15814","volume":"8","author":"S Inaguma","year":"2017","unstructured":"Inaguma S, Wang Z, Lasota J, et al. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma. Oncotarget. 2017;8(16):26744\u201354. https:\/\/doi.org\/10.18632\/oncotarget.15814.","journal-title":"Oncotarget"},{"key":"1367_CR29","doi-asserted-by":"publisher","unstructured":"Hilliard TS, Kowalski B, Iwamoto K, et al. Host mesothelin expression increases ovarian cancer metastasis in the peritoneal microenvironment. Int J Mol Sci. 2021;22(22). https:\/\/doi.org\/10.3390\/ijms222212443.","DOI":"10.3390\/ijms222212443"},{"issue":"8","key":"1367_CR30","doi-asserted-by":"publisher","first-page":"e104388","DOI":"10.1371\/journal.pone.0104388","volume":"9","author":"J Zhang","year":"2014","unstructured":"Zhang J, Bera TK, Liu W, et al. Megakaryocytic potentiating factor and mature mesothelin stimulate the growth of a lung cancer cell line in the peritoneal cavity of mice. PLoS One. 2014;9(8):e104388. https:\/\/doi.org\/10.1371\/journal.pone.0104388.","journal-title":"PLoS One"},{"key":"1367_CR31","doi-asserted-by":"publisher","unstructured":"Shin SJ, Park S, Kim MH, et al. Mesothelin expression is a predictive factor for peritoneal recurrence in curatively resected stage III gastric cancer. Oncologist. 2019;24(11):e1108-e1114. https:\/\/doi.org\/10.1634\/theoncologist.2018-0896.","DOI":"10.1634\/theoncologist.2018-0896"},{"issue":"7","key":"1367_CR32","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/jso.26610","volume":"124","author":"DH Yoon","year":"2021","unstructured":"Yoon DH, Ibrahim A, Tatishchev S, Duldulao MPN, Lee SW, Shin J. Prevalence of mesothelin expression in peritoneal disease from colorectal and appendiceal cancers. J Surg Oncol. 2021;124(7):1091\u20137. https:\/\/doi.org\/10.1002\/jso.26610.","journal-title":"J Surg Oncol"},{"key":"1367_CR33","doi-asserted-by":"publisher","unstructured":"Coelho R, Ricardo S, Amaral AL, et al. Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation. Oncogenesis. 2020;9(6):61. https:\/\/doi.org\/10.1038\/s41389-020-00246-2.","DOI":"10.1038\/s41389-020-00246-2"},{"issue":"7","key":"1367_CR34","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/sj.bjc.6604964","volume":"100","author":"WF Cheng","year":"2009","unstructured":"Cheng WF, Huang CY, Chang MC, et al. High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer. 2009;100(7):1144\u201353. https:\/\/doi.org\/10.1038\/sj.bjc.6604964.","journal-title":"Br J Cancer"},{"issue":"9396","key":"1367_CR35","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","volume":"362","author":"BW Robinson","year":"2003","unstructured":"Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362(9396):1612\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(03)14794-0.","journal-title":"Lancet"},{"issue":"20","key":"1367_CR36","doi-asserted-by":"publisher","first-page":"11531","DOI":"10.1073\/pnas.96.20.11531","volume":"96","author":"N Scholler","year":"1999","unstructured":"Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin\/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A. 1999;96(20):11531\u20136. https:\/\/doi.org\/10.1073\/pnas.96.20.11531.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1367_CR37","doi-asserted-by":"publisher","unstructured":"Linch M, Gennatas S, Kazikin S, et al. A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice. BMC Cancer. 2014;14:674. https:\/\/doi.org\/10.1186\/1471-2407-14-674.","DOI":"10.1186\/1471-2407-14-674"},{"key":"1367_CR38","doi-asserted-by":"publisher","unstructured":"Fontana V, Vigani A, Pistillo MP, et al. The correlation of serum mesothelin level with pleural thickness in malignant pleural mesothelioma makes it a valuable tool for monitoring tumor progression. J Thorac Oncol. 2019;14(5):e92-e94. https:\/\/doi.org\/10.1016\/j.jtho.2018.12.026. (This study demonstrated the change in serum mesothelin level and tumour response or progression according to mRECIST.)","DOI":"10.1016\/j.jtho.2018.12.026"},{"issue":"17","key":"1367_CR39","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","volume":"13","author":"A Cristaudo","year":"2007","unstructured":"Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res. 2007;13(17):5076\u201381. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0629.","journal-title":"Clin Cancer Res"},{"key":"1367_CR40","doi-asserted-by":"publisher","unstructured":"Grosso F, Mannucci M, Ugo F, et al. Pilot study to evaluate serum soluble mesothelin-related peptide (SMRP) as Marker for clinical monitoring of pleural mesothelioma (PM): correlation with modified RECIST score. Diagnostics (Basel). 2021;11(11):2015. https:\/\/doi.org\/10.3390\/diagnostics11112015.","DOI":"10.3390\/diagnostics11112015"},{"issue":"6","key":"1367_CR41","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00404-013-3128-x","volume":"289","author":"X Wu","year":"2014","unstructured":"Wu X, Li D, Liu L, Liu B, Liang H, Yang B. Serum soluble mesothelin-related peptide (SMRP): a potential diagnostic and monitoring marker for epithelial ovarian cancer. Arch Gynecol Obstet. 2014;289(6):1309\u201314. https:\/\/doi.org\/10.1007\/s00404-013-3128-x.","journal-title":"Arch Gynecol Obstet"},{"issue":"18","key":"1367_CR42","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1158\/1078-0432.CCR-13-0489","volume":"19","author":"F Collinson","year":"2013","unstructured":"Collinson F, Hutchinson M, Craven RA, et al. Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res. 2013;19(18):5227\u201339. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0489.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1367_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1006\/gyno.2002.6603","volume":"85","author":"K Sj\u00f6vall","year":"2002","unstructured":"Sj\u00f6vall K, Nilsson B, Einhorn N. The significance of serum CA 125 elevation in malignant and nonmalignant diseases. Gynecol Oncol. 2002;85(1):175\u20138. https:\/\/doi.org\/10.1006\/gyno.2002.6603.","journal-title":"Gynecol Oncol"},{"issue":"44","key":"1367_CR44","doi-asserted-by":"publisher","first-page":"77872","DOI":"10.18632\/oncotarget.20845","volume":"8","author":"T Eguchi","year":"2017","unstructured":"Eguchi T, Kadota K, Mayor M, et al. Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. Oncotarget. 2017;8(44):77872\u201382. https:\/\/doi.org\/10.18632\/oncotarget.20845.","journal-title":"Oncotarget"},{"issue":"6","key":"1367_CR45","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1074\/jbc.M806776200","volume":"284","author":"O Kaneko","year":"2009","unstructured":"Kaneko O, Gong L, Zhang J, et al. A binding domain on mesothelin for CA125\/MUC16. J Biol Chem. 2009;284(6):3739\u201349. https:\/\/doi.org\/10.1074\/jbc.M806776200.","journal-title":"J Biol Chem"},{"issue":"2","key":"1367_CR46","doi-asserted-by":"publisher","first-page":"574","DOI":"10.7150\/ijbs.52097","volume":"17","author":"Q Huo","year":"2021","unstructured":"Huo Q, Xu C, Shao Y, et al. Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding mesothelin to reduce DKK1 expression and activate the SGK3\/FOXO3 pathway. Int J Biol Sci. 2021;17(2):574\u201388. https:\/\/doi.org\/10.7150\/ijbs.52097.","journal-title":"Int J Biol Sci"},{"issue":"1\u20132","key":"1367_CR47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11010-012-1448-y","volume":"372","author":"S Shankar","year":"2013","unstructured":"Shankar S, Marsh L, Srivastava RK. EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1\/FOXO3a and neuropilin. Mol Cell Biochem. 2013;372(1\u20132):83\u201394. https:\/\/doi.org\/10.1007\/s11010-012-1448-y.","journal-title":"Mol Cell Biochem"},{"key":"1367_CR48","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/srep01870","volume":"3","author":"SH Chen","year":"2013","unstructured":"Chen SH, Hung WC, Wang P, Paul C, Konstantopoulos K. Mesothelin binding to CA125\/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep. 2013;3:1870. https:\/\/doi.org\/10.1038\/srep01870.","journal-title":"Sci Rep"},{"issue":"2","key":"1367_CR49","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1042\/BJ20110282","volume":"442","author":"MC Chang","year":"2012","unstructured":"Chang MC, Chen CA, Chen PJ, et al. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK\/ERK and JNK pathways. Biochem J. 2012;442(2):293\u2013302. https:\/\/doi.org\/10.1042\/BJ20110282.","journal-title":"Biochem J"},{"issue":"3","key":"1367_CR50","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrc745","volume":"2","author":"M Egeblad","year":"2002","unstructured":"Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161\u201374. https:\/\/doi.org\/10.1038\/nrc745.","journal-title":"Nat Rev Cancer"},{"key":"1367_CR51","doi-asserted-by":"publisher","unstructured":"Das V, Bhattacharya S, Chikkaputtaiah C, Hazra S, Pal M. The basics of epithelial-mesenchymal transition (EMT): a study from a structure, dynamics, and functional perspective. J Cell Physiol. 2019;234(9):14525\u201355. https:\/\/doi.org\/10.1002\/jcp.28160.","DOI":"10.1002\/jcp.28160"},{"key":"1367_CR52","doi-asserted-by":"publisher","first-page":"3249766","DOI":"10.1155\/2022\/3249766","volume":"2022","author":"BXJ Tune","year":"2022","unstructured":"Tune BXJ, Sim MS, Poh CL, et al. Matrix metalloproteinases in chemoresistance: regulatory roles, molecular interactions, and potential inhibitors. J Oncol. 2022;2022:3249766. https:\/\/doi.org\/10.1155\/2022\/3249766.","journal-title":"J Oncol"},{"issue":"3","key":"1367_CR53","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1042\/BJ20082196","volume":"424","author":"MC Chang","year":"2009","unstructured":"Chang MC, Chen CA, Hsieh CY, et al. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway. Biochem J. 2009;424(3):449\u201358. https:\/\/doi.org\/10.1042\/BJ20082196.","journal-title":"Biochem J"},{"key":"1367_CR54","doi-asserted-by":"publisher","unstructured":"Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin confers pancreatic cancer cell resistance to TNF-\u03b1-induced apoptosis through Akt\/PI3K\/NF-\u03baB activation and IL-6\/Mcl-1 overexpression. Mol Cancer. 2011;10:106. https:\/\/doi.org\/10.1186\/1476-4598-10-106.","DOI":"10.1186\/1476-4598-10-106"},{"issue":"7","key":"1367_CR55","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/carcin\/bgr075","volume":"32","author":"U Bharadwaj","year":"2011","unstructured":"Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin overexpression promotes autocrine IL-6\/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis. 2011;32(7):1013\u201324. https:\/\/doi.org\/10.1093\/carcin\/bgr075.","journal-title":"Carcinogenesis"},{"key":"1367_CR56","first-page":"20","volume":"7","author":"R Hassan","year":"2007","unstructured":"Hassan R, Ebel W, Routhier EL, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 2007;7:20.","journal-title":"Cancer Immun"},{"issue":"3","key":"1367_CR57","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.lungcan.2009.07.016","volume":"68","author":"R Hassan","year":"2010","unstructured":"Hassan R, Schweizer C, Lu KF, et al. Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer. 2010;68(3):455\u20139. https:\/\/doi.org\/10.1016\/j.lungcan.2009.07.016.","journal-title":"Lung Cancer"},{"issue":"24","key":"1367_CR58","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","volume":"16","author":"R Hassan","year":"2010","unstructured":"Hassan R, Cohen SJ, Phillips M, et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res. 2010;16(24):6132\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2275.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1367_CR59","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s10637-014-0196-0","volume":"33","author":"Y Fujisaka","year":"2015","unstructured":"Fujisaka Y, Kurata T, Tanaka K, et al. Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Invest New Drugs. 2015;33(2):380\u20138. https:\/\/doi.org\/10.1007\/s10637-014-0196-0.","journal-title":"Invest New Drugs"},{"issue":"23","key":"1367_CR60","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","volume":"20","author":"R Hassan","year":"2014","unstructured":"Hassan R, Kindler HL, Jahan T, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20(23):5927\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0804.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"1367_CR61","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344. https:\/\/doi.org\/10.1200\/JCO.2003.11.136.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1367_CR62","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1200\/JCO.2009.26.9944","volume":"28","author":"P Wheatley-Price","year":"2010","unstructured":"Wheatley-Price P, Yang B, Patsios D, et al. Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol. 2010;28(20):3316\u201322. https:\/\/doi.org\/10.1200\/JCO.2009.26.9944.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1367_CR63","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1073\/pnas.95.2.669","volume":"95","author":"PS Chowdhury","year":"1998","unstructured":"Chowdhury PS, Viner JL, Beers R, Pastan I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A. 1998;95(2):669\u201374. https:\/\/doi.org\/10.1073\/pnas.95.2.669.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1367_CR64","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/9872","volume":"17","author":"PS Chowdhury","year":"1999","unstructured":"Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol. 1999;17(6):568\u201372. https:\/\/doi.org\/10.1038\/9872.","journal-title":"Nat Biotechnol"},{"key":"1367_CR65","doi-asserted-by":"publisher","unstructured":"Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006;6(7):559\u201365. https:\/\/doi.org\/10.1038\/nrc1891.","DOI":"10.1038\/nrc1891"},{"issue":"15","key":"1367_CR66","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1158\/1078-0432.CCR-06-0346","volume":"12","author":"Y Zhang","year":"2006","unstructured":"Zhang Y, Xiang L, Hassan R, et al. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res. 2006;12(15):4695\u2013701. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0346.","journal-title":"Clin Cancer Res"},{"issue":"43","key":"1367_CR67","doi-asserted-by":"publisher","first-page":"17099","DOI":"10.1073\/pnas.0708101104","volume":"104","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, Xiang L, Hassan R, Pastan I. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A. 2007;104(43):17099\u2013104. https:\/\/doi.org\/10.1073\/pnas.0708101104.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"1367_CR68","doi-asserted-by":"publisher","first-page":"7166","DOI":"10.1158\/1078-0432.CCR-07-1592","volume":"13","author":"R Hassan","year":"2007","unstructured":"Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res. 2007;13(23):7166\u201371. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1592.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1367_CR69","doi-asserted-by":"publisher","first-page":"5915","DOI":"10.1158\/0008-5472.CAN-11-0466","volume":"71","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Chertov O, Zhang J, Hassan R, Pastan I. Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding. Cancer Res. 2011;71(17):5915\u201322. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-0466.","journal-title":"Cancer Res"},{"key":"1367_CR70","doi-asserted-by":"publisher","unstructured":"Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007;13(17):5144\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0869.","DOI":"10.1158\/1078-0432.CCR-07-0869"},{"issue":"16","key":"1367_CR71","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","volume":"15","author":"RJ Kreitman","year":"2009","unstructured":"Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res. 2009;15(16):5274\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0062.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"1367_CR72","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1002\/cncr.28875","volume":"120","author":"R Hassan","year":"2014","unstructured":"Hassan R, Sharon E, Thomas A, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer. 2014;120(21):3311\u20139. https:\/\/doi.org\/10.1002\/cncr.28875.","journal-title":"Cancer"},{"issue":"8","key":"1367_CR73","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1158\/1535-7163.MCT-14-0089-T","volume":"13","author":"K Hollevoet","year":"2014","unstructured":"Hollevoet K, Mason-Osann E, Liu XF, Imhof-Jung S, Niederfellner G, Pastan I. In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer. Mol Cancer Ther. 2014;13(8):2040\u20139. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0089-T.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"1367_CR74","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1158\/1535-7163.MCT-14-0132","volume":"13","author":"C Alewine","year":"2014","unstructured":"Alewine C, Xiang L, Yamori T, Niederfellner G, Bosslet K, Pastan I. Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers. Mol Cancer Ther. 2014;13(11):2653\u201361. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0132.","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"1367_CR75","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.1002\/cncr.33145","volume":"126","author":"R Hassan","year":"2020","unstructured":"Hassan R, Alewine C, Mian I, et al. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. Cancer. 2020;126(22):4936\u201347. https:\/\/doi.org\/10.1002\/cncr.33145.","journal-title":"Cancer."},{"key":"1367_CR76","doi-asserted-by":"publisher","unstructured":"Leshem Y, King EM, Mazor R, Reiter Y, Pastan I. SS1P immunotoxin induces markers of immunogenic cell death and enhances the effect of the CTLA-4 blockade in AE17M mouse mesothelioma tumors. Toxins (Basel). 2018;10(11):470. https:\/\/doi.org\/10.3390\/toxins10110470.","DOI":"10.3390\/toxins10110470"},{"key":"1367_CR77","doi-asserted-by":"publisher","unstructured":"Leshem Y, O'Brien J, Liu X, et al. Combining local immunotoxins targeting mesothelin with CTLA-4 blockade synergistically eradicates murine cancer by promoting anticancer immunity. Cancer Immunol Res. 2017;5(8):685\u2013694. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0330. (The first article to demonstrate preclinical evidence of synergistic anto-tumour activity of mesothelin targeting in combination with anti-CTLA4.)","DOI":"10.1158\/2326-6066.CIR-16-0330"},{"key":"1367_CR78","doi-asserted-by":"publisher","unstructured":"Jiang Q, Ghafoor A, Mian I, et al. Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. Sci Transl Med. 2020;12(550):eaaz7252. https:\/\/doi.org\/10.1126\/scitranslmed.aaz7252.","DOI":"10.1126\/scitranslmed.aaz7252"},{"key":"1367_CR79","doi-asserted-by":"publisher","unstructured":"Alewine C, Ahmad M, Peer CJ, et al. Phase I\/II study of the mesothelin-targeted immunotoxin LMB-100 with Nab-paclitaxel for patients with advanced pancreatic adenocarcinoma. Clin Cancer Res. 2020;26(4):828\u2013836. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2586.","DOI":"10.1158\/1078-0432.CCR-19-2586"},{"issue":"6","key":"1367_CR80","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1158\/1078-0432.CCR-16-1667","volume":"23","author":"J Zhang","year":"2017","unstructured":"Zhang J, Khanna S, Jiang Q, et al. Efficacy of anti-mesothelin Immunotoxin RG7787 plus Nab-paclitaxel against mesothelioma patient-derived xenografts and mesothelin as a biomarker of tumor response. Clin Cancer Res. 2017;23(6):1564\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1667.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1367_CR81","doi-asserted-by":"publisher","first-page":"9189","DOI":"10.18632\/oncotarget.13984","volume":"8","author":"E Kolyvas","year":"2017","unstructured":"Kolyvas E, Rudloff M, Poruchynsky M, et al. Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes. Oncotarget. 2017;8(6):9189\u201399. https:\/\/doi.org\/10.18632\/oncotarget.13984.","journal-title":"Oncotarget"},{"issue":"6","key":"1367_CR82","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","volume":"13","author":"S Golfier","year":"2014","unstructured":"Golfier S, Kopitz C, Kahnert A, et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther. 2014;13(6):1537\u201348. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0926.","journal-title":"Mol Cancer Ther"},{"key":"1367_CR83","doi-asserted-by":"publisher","unstructured":"Lazzerini L, J\u00f6hrens K, Sehouli J, Cichon G. Favorable therapeutic response after anti-mesothelin antibody-drug conjugate treatment requires high expression of Mesothelin in tumor cells. Arch Gynecol Obstet. 2020;302(5):1255\u20131262. https:\/\/doi.org\/10.1007\/s00404-020-05734-9.","DOI":"10.1007\/s00404-020-05734-9"},{"key":"1367_CR84","doi-asserted-by":"publisher","unstructured":"Hassan R, Blumenschein GR, Moore KN, et al. First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors. J Clin Oncol. 2020;38(16):1824\u20131835. https:\/\/doi.org\/10.1200\/JCO.19.02085.","DOI":"10.1200\/JCO.19.02085"},{"key":"1367_CR85","doi-asserted-by":"publisher","unstructured":"Kindler HL, Novello S, Bearz A, et al. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol.2022;23(4):540\u2013552. https:\/\/doi.org\/10.1016\/S1470-2045(22)00061-4.","DOI":"10.1016\/S1470-2045(22)00061-4"},{"key":"1367_CR86","doi-asserted-by":"crossref","unstructured":"Hassan R, Wang D, Wrangle J, et al. Phase Ib study of anteumab ravtansine in combination with pemetrexed and cisplatin in patients with mesothelin-expressing epithelial mesothelioma or nonsquamous non-small cell lung cancer. Mol Cancer Ther 2018; 17(1):Abstract A095.","DOI":"10.1158\/1535-7163.TARG-17-A095"},{"key":"1367_CR87","doi-asserted-by":"crossref","unstructured":"Lheureux S, Algaisi H, Cohn DE, et al. A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI 10150. J Clin Oncol. 2022;40(16_suppl_01):5514.","DOI":"10.1200\/JCO.2022.40.16_suppl.5514"},{"key":"1367_CR88","doi-asserted-by":"crossref","unstructured":"Spiliopoulou P, Kasi A, Abushahin LI, et al. Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208. J Clin Oncol. 2022;40(16_suppl_01):4136.","DOI":"10.1200\/JCO.2022.40.16_suppl.4136"},{"issue":"3","key":"1367_CR89","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1158\/1535-7163.MCT-15-0693","volume":"15","author":"CD Weekes","year":"2016","unstructured":"Weekes CD, Lamberts LE, Borad MJ, et al. Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. Mol Cancer Ther. 2016;15(3):439\u201347. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0693.","journal-title":"Mol Cancer Ther"},{"key":"1367_CR90","doi-asserted-by":"publisher","unstructured":"Rottey S, Clarke J, Aung K, et al. Phase I\/IIa trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors. Clin Cancer Res. 2022;28(1):95\u2013105. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1181. (The first human study that demonstrated at least additive anti-tumour activity when PD(L)1 anitbody was combined with mesothelin antibody drug conjugates.)","DOI":"10.1158\/1078-0432.CCR-21-1181"},{"issue":"6024","key":"1367_CR91","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331(6024):1612\u20136. https:\/\/doi.org\/10.1126\/science.1198443.","journal-title":"Science"},{"key":"1367_CR92","doi-asserted-by":"publisher","unstructured":"Luke JJ, Barlesi F, Chung K, et al. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. 2021;9(2):e002015. https:\/\/doi.org\/10.1136\/jitc-2020-002015.","DOI":"10.1136\/jitc-2020-002015"},{"key":"1367_CR93","doi-asserted-by":"publisher","unstructured":"Bouwstra R, van Meerten T, Bremer E. CD47-SIRP\u03b1 blocking-based immunotherapy: current and prospective therapeutic strategies. Clin Transl Med. 2022;12(8):e943. https:\/\/doi.org\/10.1002\/ctm2.943. (A recent review on the role of CD-47-SIRP-\u03b1 as a novel innate immune checkpoint target in solid tumours and its potential therapeutic role in mesothelioma.)","DOI":"10.1002\/ctm2.943"},{"issue":"12","key":"1367_CR94","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2115022.","journal-title":"N Engl J Med"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01367-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-023-01367-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01367-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T11:08:51Z","timestamp":1680520131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-023-01367-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":94,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1367"],"URL":"https:\/\/doi.org\/10.1007\/s11912-023-01367-8","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"14 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Advisory board and honoraria: Abbvie, Amgen, AnHeart Therapeutics, Astellas, Astra Zeneca, Boehringer Ingelheim, Bristol MyerSquibb, Eli Lilly, Jazz Pharmaceutical, Johnson and Johnson, Merck, Novartis, Pfizer, Roche, Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"Merck KGaA, Treadwell Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Safety Monitoring"}}]}}